Clinical evidence for immunomodulation induced by high-dose melphalan and autologous blood stem cell transplantation as cause for complete clinical remission of multiple myeloma-associated cryoglobulin-vasculitis.
We present a case report of a patient with cryoglobulin-vasculitis caused by multiple myeloma in Durie/Salmon stage I refractory to conventional therapy modalities treated with high-dose chemotherapy followed by autologous blood stem cell transplantation. While clinical symptoms of vasculitis disappeared, elevated cryoglobulin levels persisted. Therefore we conclude that the relief of symptoms was caused by an immunomodulation induced by the autologous stem cell transplantation.
Department of Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. jens.hillengass@med.uni-heidelberg.de.
J
J
Hillengass
Department of Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
A D
AD
Ho
Department of Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
H
H
Goldschmidt
Gemeinschaftspraxis Pathologie, Hebelstrasse 8, 69115, Heidelberg, Germany.
R
R
Waldherr
Department of Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
T M
TM
Moehler
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D003450:Cryoglobulins / Q000276:immunology; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D014182:Transplantation, Autologous; D014657:Vasculitis / Q000276:immunology / Q000628:therapy*
D018906:Antineoplastic Agents, Alkylating; D003450:Cryoglobulins; D008558:Melphalan